BackShanghai Haohai Biological Technology , Ltd. Overview

Shanghai Haohai Biological Technology , Ltd. Inventory

Shanghai Haohai Biological Technology , Ltd.'s inventory is $520M.

Get informed when a big investor buys or sells

+ Follow
Inventory
$522.35M
↑ 5.37% YoYΔ $26.64M vs prior year quarter

Peer trimmed avg / median

Loading

Shanghai Haohai Biological Technology , Ltd. Inventory History

Loading

Shanghai Haohai Biological Technology , Ltd. vs. peers: Inventory Comparison

Loading

Shanghai Haohai Biological Technology , Ltd. Inventory Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Shanghai Haohai Biological Technology , Ltd. (6826.HK) FAQ

Shanghai Haohai Biological Technology , Ltd.'s inventory stands at $520M as of June 2026. That compares with $500M in the prior-year period — up 5.4% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Shanghai Haohai Biological Technology , Ltd. reported $520M in inventory versus $500M a year earlier — a 5.4% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $500M in the prior-year period — up 5.4% year over year. Sustained growth in inventory can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Shanghai Haohai Biological Technology , Ltd.'s inventory evolved across reporting periods, while the comparison chart places 6826.HK next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, inventory is commonly used to spot outliers. Shanghai Haohai Biological Technology , Ltd.'s reading of $520M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.